Fig. 2

Enhanced engraftment of lower- and higher-risk myelodysplastic syndrome (MDS) in MISTRG mice. a–c Analysis of huCD45 engraftment was performed as detailed in Fig. 1a at >12 weeks post transplantation. a Analysis of MDS-5q-, -SLD-, -MLD-, and -MLD-RS-engrafted NSG and MISTRG mice. b Analysis of MDS/MPN and MDS-EB-1-engrafted NSG and MISTRG mice. c Analysis of MDS-EB-2-engrafted NSG and MISTRG mice. MISTRG afford significantly higher engraftment than NSG in lower- and higher-grade MDS. d–f Relative distribution of myeloid CD33⁺ (red), B-lymphoid CD19⁺ (blue), and T-lymphoid CD3⁺ (gray) cells as % of human CD45⁺ cells in NSG vs. MISTRG mice. Stacked bar graphs represent means ± S.E.M. Mann–Whitney test; n.s. not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. g Split-donor huCD45⁺ BM engraftment in NSG (black) versus MISTRG (red) mice plotted against CD34⁺ cell number injected/mouse. Individual mice are represented by symbols. Linear regression, Pearson's correlations and p values of % engraftment to CD34⁺ cell number in NSG (r = 0.39, p < 0.0001) vs. MISTRG (r = 0.42, p < 0.0001) are displayed. h Percentage of transplanted mice with huCD45⁺ bonemarrow (BM) engraftment levels >0.01% < 1%, 1–10%, and >10% for split-donor grafts in NSG (59/111, 44/111, and 8/111, respectively) and MISTRG (20/154, 51/154, and 83/154, respectively) mice (Fisher’s exact test, ****p < 0.0001 for NSG vs. MISTRG). For detailed patient sample information see Supplementary Table 1. SLD single lineage dysplasia; MLD multi lineage dysplasia; RS Ringsideroblasts; MPN myeloproliferative neoplasm